Your browser is no longer supported. Please, upgrade your browser.
AVDL Avadel Pharmaceuticals plc monthly Stock Chart
Avadel Pharmaceuticals plc
Index- P/E- EPS (ttm)-0.08 Insider Own0.50% Shs Outstand58.21M Perf Week9.53%
Market Cap426.84M Forward P/E- EPS next Y-1.32 Insider Trans- Shs Float35.59M Perf Month46.18%
Income6.40M PEG- EPS next Q-0.28 Inst Own56.00% Short Float11.68% Perf Quarter4.33%
Sales33.30M P/S12.82 EPS this Y65.30% Inst Trans-12.93% Short Ratio5.63 Perf Half Y-6.74%
Book/sh2.94 P/B2.54 EPS next Y-1785.70% ROA6.10% Target Price- Perf Year20.29%
Cash/sh4.05 P/C1.84 EPS next 5Y15.00% ROE17.50% 52W Range4.00 - 13.49 Perf YTD-1.06%
Dividend- P/FCF- EPS past 5Y18.50% ROI-23.20% 52W High-44.63% Beta1.53
Dividend %- Quick Ratio12.20 Sales past 5Y31.60% Gross Margin75.50% 52W Low86.75% ATR0.43
Employees50 Current Ratio12.20 Sales Q/Q- Oper. Margin- RSI (14)72.13 Volatility5.32% 7.11%
OptionableYes Debt/Eq0.00 EPS Q/Q15.10% Profit Margin46.70% Rel Volume0.35 Prev Close7.31
ShortableYes LT Debt/Eq0.74 EarningsNov 09 BMO Payout0.00% Avg Volume738.06K Price7.47
Recom1.40 SMA2020.43% SMA5030.56% SMA200-1.74% Volume258,544 Change2.19%
Jul-31-20Initiated Oppenheimer Outperform $19
Jul-21-20Initiated SVB Leerink Outperform $17
Jun-30-20Initiated H.C. Wainwright Buy $15
Apr-03-20Initiated Jefferies Buy $14
Mar-12-20Initiated Stifel Buy $14
Feb-26-20Initiated Piper Sandler Overweight $14
Jan-30-20Initiated Craig Hallum Buy $15
Jun-14-19Upgrade Ladenburg Thalmann Neutral → Buy $6
Feb-08-19Downgrade Ladenburg Thalmann Buy → Neutral
Nov-23-20 08:00AM  
Nov-11-20 08:00AM  
Nov-09-20 06:30PM  
Oct-26-20 08:00AM  
Oct-07-20 10:38AM  
Sep-30-20 06:58AM  
Sep-17-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 04:35PM  
Aug-18-20 08:42AM  
Aug-11-20 01:30AM  
Aug-10-20 08:34AM  
Aug-05-20 03:31PM  
Aug-01-20 08:12AM  
Jul-27-20 08:00AM  
Jul-13-20 08:00AM  
Jul-03-20 07:05AM  
Jul-01-20 08:00AM  
Jun-27-20 09:13PM  
Jun-08-20 08:00AM  
Jun-01-20 09:20AM  
May-28-20 05:54AM  
May-11-20 02:30PM  
May-09-20 08:10AM  
May-06-20 07:04AM  
May-04-20 04:05PM  
Apr-28-20 08:28PM  
Apr-27-20 06:07PM  
Apr-23-20 08:46AM  
Apr-15-20 09:23AM  
Apr-08-20 10:02AM  
Mar-25-20 08:00AM  
Mar-14-20 08:26AM  
Mar-13-20 06:56AM  
Mar-12-20 07:00AM  
Mar-11-20 12:27PM  
Feb-27-20 08:30AM  
Feb-21-20 09:00AM  
Jan-28-20 02:59AM  
Jan-23-20 10:42AM  
Jan-21-20 08:41AM  
Jan-13-20 05:26AM  
Jan-10-20 08:00AM  
Jan-06-20 12:00PM  
Dec-23-19 07:54AM  
Dec-19-19 11:15AM  
Dec-17-19 12:00PM  
Dec-16-19 08:00AM  
Dec-15-19 03:49PM  
Dec-10-19 08:00AM  
Dec-09-19 10:04AM  
Dec-06-19 03:07PM  
Dec-02-19 08:00AM  
Nov-29-19 08:13AM  
Nov-27-19 07:01AM  
Nov-26-19 08:06AM  
Nov-25-19 08:00AM  
Nov-21-19 08:00AM  
Nov-18-19 09:01AM  
Nov-14-19 05:14AM  
Nov-12-19 07:00AM  
Oct-29-19 08:00AM  
Oct-04-19 04:05PM  
Sep-24-19 07:30AM  
Sep-23-19 07:55AM  
Sep-18-19 07:30AM  
Sep-17-19 07:30AM  
Sep-15-19 09:22AM  
Aug-13-19 11:12AM  
Aug-09-19 07:00AM  
Aug-08-19 04:05PM  
Aug-01-19 07:00AM  
Jul-29-19 07:00AM  
Jul-17-19 12:39PM  
Jul-10-19 10:22AM  
Jun-18-19 09:45AM  
Jun-04-19 07:00AM  
Jun-03-19 07:06AM  
May-22-19 08:00AM  
May-08-19 10:16AM  
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCHUGH THOMAS SChief Financial OfficerSep 18Buy6.004,00024,00021,500Sep 21 04:01 PM
Ende Eric JDirectorSep 17Buy5.7917,00098,37684,900Sep 18 04:19 PM
McCamish Mark AnthonyDirectorSep 17Buy5.8352,398305,250171,000Sep 18 04:20 PM
McCamish Mark AnthonyDirectorSep 16Buy5.73118,602679,969118,602Sep 18 04:20 PM
MCHUGH THOMAS SChief Financial OfficerAug 28Buy6.777,50050,77717,500Sep 01 04:12 PM
Glass Geoffrey MichaelDirectorAug 28Buy6.784,80032,56065,700Sep 01 04:11 PM
Palczuk LindaDirectorAug 14Buy7.942,50019,85037,900Aug 17 06:58 PM
MCHUGH THOMAS SChief Financial OfficerAug 13Buy7.7810,00077,81410,000Aug 17 06:59 PM
Ende Eric JDirectorAug 13Buy7.795,00038,92867,900Aug 17 06:57 PM
Glass Geoffrey MichaelDirectorAug 13Buy7.766,50050,44060,900Aug 14 06:11 PM
Glass Geoffrey MichaelDirectorAug 12Buy7.706,50050,05054,400Aug 14 06:11 PM
Divis Gregory JChief Executive OfficerAug 12Buy7.7813,000101,15699,100Aug 13 07:39 PM
Ende Eric JDirectorAug 12Buy7.7615,000116,35562,900Aug 13 07:40 PM
Hatten Sandra LSee RemarksDec 12Sale7.233,07222,21155,765Dec 16 04:21 PM
Ende Eric JDirectorDec 04Buy5.9710,00059,70047,900Dec 05 04:30 PM
Palczuk LindaDirectorDec 03Buy5.917,50044,32535,400Dec 05 04:29 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.